165 related articles for article (PubMed ID: 24121210)
1. Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.
Jim HS; Quinn GP; Gwede CK; Cases MG; Barata A; Cessna J; Christie J; Gonzalez L; Koskan A; Pidala J
Bone Marrow Transplant; 2014 Feb; 49(2):299-303. PubMed ID: 24121210
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients.
Jamani K; Onstad LE; Bar M; Carpenter PA; Krakow EF; Salit RB; Flowers MED; Lee SJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2271-2276. PubMed ID: 29935213
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation.
El-Jawahri AR; Traeger LN; Kuzmuk K; Eusebio JR; Vandusen HB; Shin JA; Keenan T; Gallagher ER; Greer JA; Pirl WF; Jackson VA; Ballen KK; Spitzer TR; Graubert TA; McAfee SL; Dey BR; Chen YB; Temel JS
Cancer; 2015 Mar; 121(6):951-9. PubMed ID: 25469752
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention.
Pidala J; Anasetti C; Jim H
Br J Haematol; 2010 Feb; 148(3):373-85. PubMed ID: 19919651
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients.
Mathanda RR; Hamilton BK; Rybicki L; Advani AS; Colver A; Dabney J; Ferraro C; Hanna R; Kalaycio M; Lawrence C; McLellan L; Sobecks R; Majhail NS; Rotz SJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1505-1510. PubMed ID: 32439476
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for allogeneic haematopoietic stem cell transplantation: how much benefit is worthwhile from the patient's perspective?
Leuthold N; Cattaneo M; Halter J; Hügli C; Kirsch M; Petropoulou A; Erlanger TE; Gerull S; Passweg J; O'Meara Stern A
Support Care Cancer; 2021 Jun; 29(6):3129-3135. PubMed ID: 33067766
[TBL] [Abstract][Full Text] [Related]
8. Quality of life after allogeneic hematopoietic cell transplantation.
Pidala J; Anasetti C; Jim H
Blood; 2009 Jul; 114(1):7-19. PubMed ID: 19336756
[TBL] [Abstract][Full Text] [Related]
9. Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study.
Devins GM; Mah K; Messner HA; Xenocostas A; Gauvin L; Lipton JH
Support Care Cancer; 2018 Jul; 26(7):2379-2386. PubMed ID: 29423678
[TBL] [Abstract][Full Text] [Related]
10. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey.
Kurosawa S; Yamaguchi T; Oshima K; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Fujisawa S; Onishi Y; Yano S; Onizuka M; Kanda Y; Mizuno I; Taniguchi S; Yamashita T; Inamoto Y; Okamoto S; Atsuta Y
Bone Marrow Transplant; 2019 Apr; 54(4):611-615. PubMed ID: 30287939
[No Abstract] [Full Text] [Related]
11. Circadian Rhythmicity as a Predictor of Quality of Life in Allogeneic Hematopoietic Cell Transplant Patients.
Hoogland AI; Bulls HW; Gonzalez BD; Small BJ; Liu L; Pidala J; Jim HSL; Mishra A
J Pain Symptom Manage; 2019 May; 57(5):952-960.e1. PubMed ID: 30711631
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia.
Wright R; Oremek M; Davies D; Kewley C; Singh A; Taitt N; Kempshall E; Wilson K; Ingram W
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1527-1533. PubMed ID: 32422252
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life in leukemia Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning.
González-Ramírez MP; Miravete-Lagunes K; Gómez-de-León A; Ponce-de-León S; Tenorio-Rojo AP; Martagón-Herrera NA; Hernández-Reyes JA; García-Villasenor A; Burguette E; Vallejo-Villalobos MF; Ruiz-Delgado GJ; Gómez-Almaguer D; Ruiz-Argüelles GJ
Rev Invest Clin; 2015; 67(2):109-16. PubMed ID: 25938844
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Wood WA; Le-Rademacher J; Syrjala KL; Jim H; Jacobsen PB; Knight JM; Abidi MH; Wingard JR; Majhail NS; Geller NL; Rizzo JD; Fei M; Wu J; Horowitz MM; Lee SJ
Cancer; 2016 Jan; 122(1):91-8. PubMed ID: 26439325
[TBL] [Abstract][Full Text] [Related]
15. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
[TBL] [Abstract][Full Text] [Related]
16. Parent proxy assessment of sibling quality of life following pediatric hematopoietic cell transplantation.
Buchbinder D; Patel SK; Casillas JN; Nugent DJ; Neudorf S; Sender LS; Torno L; Huszti H; Zeltzer LK; Parsons SK
Health Qual Life Outcomes; 2019 Oct; 17(1):162. PubMed ID: 31665035
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
[TBL] [Abstract][Full Text] [Related]
18. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
19. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes.
Rezvani AR; Sandmaier BM
Curr Opin Hematol; 2013 Nov; 20(6):509-14. PubMed ID: 24104411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
